Skip to main content

Table 2 Baseline Echocardiographic Parameters

From: Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study

  Trimetazidine Placebo
LA (mm) 52.6 ± 2.1 51.9 ± 1.7
LVEDD (mm) 63.2 ± 2.1 62.4 ± 1.7
LVESD (mm) 41.1 ± 1.5 39.5 ± 1.3
LVEF (%) 32.3 ± 5.3 32.8 ± 2.3
LV Wall Motion Index Score 1.37 ± 0.2 1.38 ± 0.3
E/A 0.68 ± 0.1 0.64 ± 0.12
  1. Baseline echocardiographic parameters in patients randomized to trimetazidine or placebo. No significant differences in echocardiographic and Doppler measures were found between the two groups at baseline.
Back to article page